Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

88.47USD
20 Jul 2018
Change (% chg)

$-0.96 (-1.07%)
Prev Close
$89.43
Open
$89.21
Day's High
$89.28
Day's Low
$88.27
Volume
1,102,155
Avg. Vol
1,082,260
52-wk High
$90.12
52-wk Low
$73.70

Select another date:

Wed, Jul 18 2018

Photo

Pfizer-Lilly pain drug meets late-stage trial goals

An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids.

Pfizer-Lilly pain drug found effective in late-stage study

July 18 An experimental drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of reducing pain in osteoarthritis patients in a late stage trial, the companies said on Wednesday.

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.

UPDATE 2-Lilly gets U.S. nod for arthritis drug, sets price well below rivals

* Drug priced at $25,000/year, 60 pct lower to AbbVie's Humira

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.

Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors.

Eli Lilly to buy cancer drug developer AurKa Pharma

May 14 Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held company's experimental cancer treatment for solid tumors.

BRIEF-HBM Healthcare Investments: Eli Lilly Announces Tender Offer For HBM-Portfolio Company

* ELI LILLY ANNOUNCES TENDER OFFER FOR HBM-PORTFOLIO COMPANY ARMO BIOSCIENCES FOR USD 1.6 BILLION

BRIEF-Armo Biosciences - Upon Termination Of Merger Under Specified Circumstances Co May Be Required To Pay Eli Lilly Fee Of $63.4 Mln

* ARMO BIOSCIENCES - UPON TERMINATION OF MERGER UNDER SPECIFIED CIRCUMSTANCES CO MAY BE REQUIRED TO PAY ELI LILLY TERMINATION FEE OF $63.4 MILLION Source: (https://bit.ly/2I7j4vd) Further company coverage:

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.

Select another date: